• The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030

    In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder

    Roots Analysis has announced the addition of “RNA Therapeutics Market” report to its list of offerings.

    RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers.

    To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html

    Key Market Insights

    100+ RNA targeting small molecules therapeutics have been / are being developed for the treatment of different types of disease indications
    Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively.

    More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage
    Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development

    Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development
    Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification.

    More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies
    North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders

    Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020
    More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%).

    Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders
    Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US.

    North America is anticipated to capture over ~70% of the global market share in 2030
    In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html

    Key Questions Answered
     Who are the key players engaged in the development of RNA targeting small molecule therapeutics?
     What are the current investment trends in this field?
     Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?
     What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?
     What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
     What is the relative competitiveness of different RNA targeting small molecules therapeutics developers engaged in this market?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:

     Drug
     Translarna™
     Risdiplam
     Tomivosertib
     ELX-02
     H3B-6545
     ABX464

     Type of Indication
     Aniridia
     Breast Cancer
     Castrate-resistant Prostate Cancer
     Colorectal Cancer
     Crohn Disease
     Cystic Fibrosis
     Duchenne Muscular Dystrophy
     Dravet Syndrome
     HIV Infections
     Impaired Renal Function
     NSCLC
     Rheumatoid Arthritis
     Spinal Muscular Atrophy
     Ulcerative Colitis

     Type of Therapeutic Area
     Autoimmune Disorders
     Genetic Disorders
     Inflammatory Disorders
     Infectious Disorders
     Kidney Disorders
     Neurological Disorders
     Oncological Disorders
     Ophthalmic Disorders
     Rare Disorders
     Respiratory Disorders

     Type of Target Molecule
     CDKL5
     Cap Binding Complex
     Dystrophin Protein
     Estrogen Receptor Alpha
     G542X
     MNK1 / MNK2 PAX6 Gene
     PAX6 Gene
     SMN2

     Type of Route of Administration
     Oral
     Subcutaneous

     Key Geographical Regions
     North America
     Europe

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Abivax
     AC immune
     Arrakis Therapeutics
     eFFECTOR Therapeutics
     Eloxx Pharmaceuticals
     H3 Biomedicine
     PTC Therapeutics
     Ribometrix
     Skyhawk Therapeutics
     STORM Therapeutics


    For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030 In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder Roots Analysis has announced the addition of “RNA Therapeutics Market” report to its list of offerings. RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers. To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html Key Market Insights 100+ RNA targeting small molecules therapeutics have been / are being developed for the treatment of different types of disease indications Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively. More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification. More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020 More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%). Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US. North America is anticipated to capture over ~70% of the global market share in 2030 In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html Key Questions Answered  Who are the key players engaged in the development of RNA targeting small molecule therapeutics?  What are the current investment trends in this field?  Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?  What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?  What type of partnership models are most commonly adopted by stakeholders engaged in this domain?  What is the relative competitiveness of different RNA targeting small molecules therapeutics developers engaged in this market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:  Drug  Translarna™  Risdiplam  Tomivosertib  ELX-02  H3B-6545  ABX464  Type of Indication  Aniridia  Breast Cancer  Castrate-resistant Prostate Cancer  Colorectal Cancer  Crohn Disease  Cystic Fibrosis  Duchenne Muscular Dystrophy  Dravet Syndrome  HIV Infections  Impaired Renal Function  NSCLC  Rheumatoid Arthritis  Spinal Muscular Atrophy  Ulcerative Colitis  Type of Therapeutic Area  Autoimmune Disorders  Genetic Disorders  Inflammatory Disorders  Infectious Disorders  Kidney Disorders  Neurological Disorders  Oncological Disorders  Ophthalmic Disorders  Rare Disorders  Respiratory Disorders  Type of Target Molecule  CDKL5  Cap Binding Complex  Dystrophin Protein  Estrogen Receptor Alpha  G542X  MNK1 / MNK2 PAX6 Gene  PAX6 Gene  SMN2  Type of Route of Administration  Oral  Subcutaneous  Key Geographical Regions  North America  Europe The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Abivax  AC immune  Arrakis Therapeutics  eFFECTOR Therapeutics  Eloxx Pharmaceuticals  H3 Biomedicine  PTC Therapeutics  Ribometrix  Skyhawk Therapeutics  STORM Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    RNA Targeting Small Molecules Therapeutics Market | Market Size | Industry Analysis | 2030
    RNA Targeting Small Molecules Therapeutics / RNA translation modulators market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The RNA targeting small molecule therapies market

    In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder

    Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings.

    RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers.

    To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html.

    Key Market Insights

    100+ RNA targeting small molecule therapeutics have been / are being developed for the treatment of different types of disease indications
    Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively.

    More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage
    Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development

    Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development
    Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification.

    More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies
    North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders

    Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020
    More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%).

    Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders
    Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US.

    North America is anticipated to capture over ~70% of the global market share in 2030
    In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html

    Key Questions Answered
     Who are the key players engaged in the development of RNA targeting small molecule therapeutics?
     What are the current investment trends in this field?
     Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?
     What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?
     What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
     What is the relative competitiveness of different RNA targeting small molecule therapeutics developers engaged in this market?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:

     Drug
     Translarna™
     Risdiplam
     Tomivosertib
     ELX-02
     H3B-6545
     ABX464

     Type of Indication
     Aniridia
     Breast Cancer
     Castrate-resistant Prostate Cancer
     Colorectal Cancer
     Crohn Disease
     Cystic Fibrosis
     Duchenne Muscular Dystrophy
     Dravet Syndrome
     HIV Infections
     Impaired Renal Function
     NSCLC
     Rheumatoid Arthritis
     Spinal Muscular Atrophy
     Ulcerative Colitis

     Type of Therapeutic Area
     Autoimmune Disorders
     Genetic Disorders
     Inflammatory Disorders
     Infectious Disorders
     Kidney Disorders
     Neurological Disorders
     Oncological Disorders
     Ophthalmic Disorders
     Rare Disorders
     Respiratory Disorders

     Type of Target Molecule
     CDKL5
     Cap Binding Complex
     Dystrophin Protein
     Estrogen Receptor Alpha
     G542X
     MNK1 / MNK2 PAX6 Gene
     PAX6 Gene
     SMN2

     Type of Route of Administration
     Oral
     Subcutaneous

     Key Geographical Regions
     North America
     Europe

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Abivax
     AC immune
     Arrakis Therapeutics
     eFFECTOR Therapeutics
     Eloxx Pharmaceuticals
     H3 Biomedicine
     PTC Therapeutics
     Ribometrix
     Skyhawk Therapeutics
     STORM Therapeutics


    For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The RNA targeting small molecule therapies market In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorder Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings. RNAs represent a one-of-a-kind class of molecules that can interact with three different types of biological macromolecules, namely DNA, RNA and proteins which further enables the development of therapies capable of targeting previously deemed undruggable transcripts and genes. In the past few years, a number of novel techniques have been developed to expand the druggability of RNA molecules. As a result, numerous small molecules, capable of acting on current and novel RNA targets are also being investigated in clinical and preclinical studies for the treatment of various indications, such as genetic diseases, infectious diseases and different types of cancers. To order this 260+ page report, which features 110+ figures, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html. Key Market Insights 100+ RNA targeting small molecule therapeutics have been / are being developed for the treatment of different types of disease indications Close to 70% of the aforementioned therapeutic candidates are under preclinical evaluation. Further, two therapies, namely Translarna™ and Risdiplam, have been approved for the treatment of Duchenne Muscular Dystrophy and spinal muscular atrophy respectively. More than 45% of the therapies under clinical evaluation are currently in phase II developmental stage Around 50% of therapies under clinical evaluation are being developed to target oncological disorders; of which 53% of candidates are being evaluated under phase I clinical stage of development Close to 60% of the therapies under preclinical evaluation are currently in discovery phase of development Around 44% of the therapies under preclinical evaluation are being developed to target neurological disorders; of which close to 50% of drug candidates underwent RNA splicing modification. More than 55% of the players evaluating RNA Targeting small molecule therapies are small companies North America has emerged as a key hub, featuring the presence of 63% developers. The developer landscape is further dominated by players that have been established post-2012, representing around 68% of the total number of stakeholders Partnership activity in this field has increased at a CAGR of 9.1%, between 2018 and 2020 More than 70% of the reported deals were R&D agreements, majority of which were focused on drug candidates targeting neurological disorders. Further, majority of the instances captured in the report were inked with players based in North America (65%). Close to USD 500 million was raised by companies involved in the development of drug candidates targeting oncological disorders Majority of the companies (52%) engaged in this domain primarily received funding through venture capital rounds. Further, around 90% of the funding instances were reported by players headquartered in the US. North America is anticipated to capture over ~70% of the global market share in 2030 In 2030, close to 40% of the market revenues are expected to be generated from sales of therapeutics that are intended to target oncological disorders. Further, therapies designed for oral route of administration are expected to occupy a larger share (77%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market/request-sample.html Key Questions Answered  Who are the key players engaged in the development of RNA targeting small molecule therapeutics?  What are the current investment trends in this field?  Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?  What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?  What type of partnership models are most commonly adopted by stakeholders engaged in this domain?  What is the relative competitiveness of different RNA targeting small molecule therapeutics developers engaged in this market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD XX million (by 2030) financial opportunity within the RNA targeting small molecules therapeutics market has been analyzed across the following segments:  Drug  Translarna™  Risdiplam  Tomivosertib  ELX-02  H3B-6545  ABX464  Type of Indication  Aniridia  Breast Cancer  Castrate-resistant Prostate Cancer  Colorectal Cancer  Crohn Disease  Cystic Fibrosis  Duchenne Muscular Dystrophy  Dravet Syndrome  HIV Infections  Impaired Renal Function  NSCLC  Rheumatoid Arthritis  Spinal Muscular Atrophy  Ulcerative Colitis  Type of Therapeutic Area  Autoimmune Disorders  Genetic Disorders  Inflammatory Disorders  Infectious Disorders  Kidney Disorders  Neurological Disorders  Oncological Disorders  Ophthalmic Disorders  Rare Disorders  Respiratory Disorders  Type of Target Molecule  CDKL5  Cap Binding Complex  Dystrophin Protein  Estrogen Receptor Alpha  G542X  MNK1 / MNK2 PAX6 Gene  PAX6 Gene  SMN2  Type of Route of Administration  Oral  Subcutaneous  Key Geographical Regions  North America  Europe The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Abivax  AC immune  Arrakis Therapeutics  eFFECTOR Therapeutics  Eloxx Pharmaceuticals  H3 Biomedicine  PTC Therapeutics  Ribometrix  Skyhawk Therapeutics  STORM Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • A new research report titled global Particle Therapy Systems market report published by Reports and Data provides a brief overview of the industry and gives an estimation of growth and revenue for the forecast period of 2021-2027. The report covers profiling and study of major manufacturers of the Particle Therapy Systems market along with their sales, revenue, and market share. The report further analyzes market segments, size, trends, growth drivers, restraining factors, opportunities and challenges, cost overview, SWOT analysis, and Porter’s Five Forces Analysis. The report all includes industrial chain analysis, revenue growth, sales estimation, value chain analysis, capacity, regional market examination, and market forecast up to 2027. The report offers insightful information that will assist in gaining a market position and maximize on lucrative growth opportunities.
    Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3323

    The report provides a panoramic view of the market and insights that will help formulate better business decisions. In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions. The report also discusses in detail about the key factors influencing the market growth.
    Key companies operating in the market include:
    • Ion Beam Applications SA
    • Varian Medical Systems, Inc.
    • Hitachi, Ltd.
    • Provision Healthcare
    • Mevion Medical Systems, Inc.
    • Sumitomo Heavy Industries, Ltd.
    • Optivus Proton Therapy, Inc.
    • ProTom International, Inc.
    • Advanced Oncotherapy Plc.
    • Danfysik A/S
    The report covers an extensive analysis of the key market players in the market along with their business overview, expansion plans, and strategies. The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others.
    Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3323

    The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level. To gain a deeper understanding of the industry, the global Particle Therapy Systems market is further segmented on the basis of key geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The report also offers a country-wise analysis to provide crucial insights into market size, market growth, market revenue growth, and economic growth in each region.
    On basis of product types and application offered by the Particle Therapy Systems industry, the market is segmented into:
    By Type (Revenue, USD Million; Volume in Tons, 2017–2027)
    • Proton Therapy
    • Heavy Ion Therapy
    By System (Revenue, USD Million; Volume in Tons, 2017–2027)
    • Single room
    • Multi room
    By Service (Revenue, USD Million; Volume in Tons, 2017–2027)
    • Cyclotrons
    • Synchrotrons
    • Synchrocyclotrons
    By Cancer Type (Revenue, USD Million; Volume in Tons, 2017–2027)
    • Pediatric Cancer
    • Prostate Cancer
    • Breast Cancer
    • Lung Cancer
    • Head and Neck Cancer
    • Lymphoma
    • Sarcoma
    • Spine Cancer
    • Pancreatic Cancer
    • Brain Cancer
    • Secondary/Reoccurring Cancer
    • Gastrointestinal Cancer
    • Others
    By Application Type (Revenue, USD Million; Volume in Tons, 2017–2027)
    • Treatment
    • Research
    The regional analysis covers:
    • North America
    o U.S.
    o Canada
    o Mexico
    • Europe
    o Germany
    o U.K.
    o Italy
    o France
    o BENELUX
    o Rest of Europe
    • Asia Pacific
    o China
    o India
    o Japan
    o South Korea
    o Rest of APAC
    • Latin America
    o Brazil
    o Rest of LATAM
    • Middle East & Africa
    o Saudi Arabia
    o U.A.E.
    o South Africa
    o Rest of MEA
    To know more about the report @ https://www.reportsanddata.com/report-detail/particle-therapy-systems-market

    Benefits of Particle Therapy Systems Market Report:
    • Panoramic overview of the opportunities and risks in the Particle Therapy Systems sector
    • Study of recent innovations and developments in the industry
    • Comprehensive study of the growth pattern of the Particle Therapy Systems industry
    • In-depth assessment of the competitive landscape of the key players of the Particle Therapy Systems industry
    • Analysis of the Particle Therapy Systems market drivers, constraints, and opportunities
    • Assessment of technological developments and latest trends of the industry
    Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3323

    Thank you for reading our report. For customization or further inquiry, please get in touch with us. Our team will ensure the report is tailored according to your requirements.
    Browse More Reports :

    Wearable Healthcare/Medical Devices Market Growth Rate
    3D Imaging Market Growth Rate
    A new research report titled global Particle Therapy Systems market report published by Reports and Data provides a brief overview of the industry and gives an estimation of growth and revenue for the forecast period of 2021-2027. The report covers profiling and study of major manufacturers of the Particle Therapy Systems market along with their sales, revenue, and market share. The report further analyzes market segments, size, trends, growth drivers, restraining factors, opportunities and challenges, cost overview, SWOT analysis, and Porter’s Five Forces Analysis. The report all includes industrial chain analysis, revenue growth, sales estimation, value chain analysis, capacity, regional market examination, and market forecast up to 2027. The report offers insightful information that will assist in gaining a market position and maximize on lucrative growth opportunities. Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3323 The report provides a panoramic view of the market and insights that will help formulate better business decisions. In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions. The report also discusses in detail about the key factors influencing the market growth. Key companies operating in the market include: • Ion Beam Applications SA • Varian Medical Systems, Inc. • Hitachi, Ltd. • Provision Healthcare • Mevion Medical Systems, Inc. • Sumitomo Heavy Industries, Ltd. • Optivus Proton Therapy, Inc. • ProTom International, Inc. • Advanced Oncotherapy Plc. • Danfysik A/S The report covers an extensive analysis of the key market players in the market along with their business overview, expansion plans, and strategies. The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others. Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3323 The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level. To gain a deeper understanding of the industry, the global Particle Therapy Systems market is further segmented on the basis of key geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The report also offers a country-wise analysis to provide crucial insights into market size, market growth, market revenue growth, and economic growth in each region. On basis of product types and application offered by the Particle Therapy Systems industry, the market is segmented into: By Type (Revenue, USD Million; Volume in Tons, 2017–2027) • Proton Therapy • Heavy Ion Therapy By System (Revenue, USD Million; Volume in Tons, 2017–2027) • Single room • Multi room By Service (Revenue, USD Million; Volume in Tons, 2017–2027) • Cyclotrons • Synchrotrons • Synchrocyclotrons By Cancer Type (Revenue, USD Million; Volume in Tons, 2017–2027) • Pediatric Cancer • Prostate Cancer • Breast Cancer • Lung Cancer • Head and Neck Cancer • Lymphoma • Sarcoma • Spine Cancer • Pancreatic Cancer • Brain Cancer • Secondary/Reoccurring Cancer • Gastrointestinal Cancer • Others By Application Type (Revenue, USD Million; Volume in Tons, 2017–2027) • Treatment • Research The regional analysis covers: • North America o U.S. o Canada o Mexico • Europe o Germany o U.K. o Italy o France o BENELUX o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Rest of APAC • Latin America o Brazil o Rest of LATAM • Middle East & Africa o Saudi Arabia o U.A.E. o South Africa o Rest of MEA To know more about the report @ https://www.reportsanddata.com/report-detail/particle-therapy-systems-market Benefits of Particle Therapy Systems Market Report: • Panoramic overview of the opportunities and risks in the Particle Therapy Systems sector • Study of recent innovations and developments in the industry • Comprehensive study of the growth pattern of the Particle Therapy Systems industry • In-depth assessment of the competitive landscape of the key players of the Particle Therapy Systems industry • Analysis of the Particle Therapy Systems market drivers, constraints, and opportunities • Assessment of technological developments and latest trends of the industry Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3323 Thank you for reading our report. For customization or further inquiry, please get in touch with us. Our team will ensure the report is tailored according to your requirements. Browse More Reports : Wearable Healthcare/Medical Devices Market Growth Rate 3D Imaging Market Growth Rate
    Particle Therapy Systems Market Share & Growth, 2020-2027
    Particle therapy systems market consists of an elaborate & meticulous study that covers all the segments of this industry. the particle therapy systems market in 2019 was valued to be at USD 947.17 mn and has prospects of it growing to USD 1.95 bn by the end of 2027, growing at a CAGR of nearly 9.5%.
    WWW.REPORTSANDDATA.COM
    0 Comments 0 Shares
  • The global molecular diagnostics market size is expected to reach USD 16.16 Billion by 2028 and register a CAGR of 8.2%, according to the latest report by Reports and Data. Government initiatives to promote molecular testing, increasing geriatric population, and rising cases of various infectious diseases across the world are key factors boosting global market revenue growth.
    Molecular diagnostic techniques have gained rapid traction over the last few years and are widely used in laboratories, research institutes, and hospitals for various purposes. Increasing investments in research and development activities, growing awareness about faster diagnostic techniques, and increasing adoption of self-testing kits are fueling the revenue growth of the global market. In addition, government funding for developing advanced testing kits and instruments and rapid infrastructural developments in healthcare systems are further supporting global market revenue growth.
    However, many hospitals and reference laboratories in developing countries find it difficult to afford the costly instruments and kits. This is expected to hamper global market growth in the coming years. In addition, lack of skilled professionals to operate these instruments is expected to further restrain market growth during the forecast period.
    Get a sample of the report @ https://reportsanddata.com/sample-enquiry-form/945
    The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.
    Key players in the market include
    Abbott, Roche Diagnostics, QIAGEN, Danaher, Hologic, Becton, Siemens Healthcare GmbH, Bio-Rad Laboratories, Dickinson and Co., Cepheid
    Furthermore, the report segments Molecular Diagnostics market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.
    Product and Service Outlook (Revenue, USD Billion, 2018 - 2028)
    • Reagents and Kits
    • Instruments
    • Tabletop Instruments
    • Portable & PoC Instruments
    • Services and Software
    Technology Outlook (Revenue, USD Billion, 2018 - 2028)
    • Polymerase Chain Reaction (PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • DNA Sequencing & Next-Generation Sequencing (NGS)
    • In Situ Hybridization
    • DNA Microarray
    • Other Technologies
    Application Outlook (Revenue, USD Billion, 2018 - 2028)
    • Infectious Diseases
    • Hepatitis
    • HIV
    • CT/NG
    • HAIS
    • HPV
    • Tuberculosis
    • Influenza
    • Other Infectious Diseases
    • Oncology Testing
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Other Cancers
    • Genetic Tests
    • Others
    End-Use Outlook (Revenue, USD Billion, 2018 - 2028)
    • Hospital and Clinics
    • Diagnostic Laboratories
    • Others
    For a better understanding of the global Molecular Diagnostics market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region.
    Request a discount on the report @ https://reportsanddata.com/discount-enquiry-form/945
    In-depth regional analysis includes:
    • North America (U.S., Canada, Mexico)
    • Europe (Italy, U.K., Germany, France, Rest of EU)
    • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA
    To know more about the report @ https://reportsanddata.com/report-detail/global-molecular-diagnostics-market
    Key Features of the Global Molecular Diagnostics Market Report:
    • Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value
    • Identification and analysis of significant trends and factors driving revenue growth of the market
    • Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches
    • Assessment of each market segment along with their growth trends and market revenue contribution
    • Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks
    Request a customization of the report @ https://reportsanddata.com/request-customization-form/945
    Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.

    Browse More Reports :

    Vaginal Pessary Market Analysis
    Spinal Trauma Devices Market Share


    About Reports and Data
    Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
    Contact Us:
    John W
    Head of Business Development
    Reports and Data | Web: www.reportsanddata.com
    Direct Line: +1-212-710-1370
    E-mail: sales@reportsanddata.com
    The global molecular diagnostics market size is expected to reach USD 16.16 Billion by 2028 and register a CAGR of 8.2%, according to the latest report by Reports and Data. Government initiatives to promote molecular testing, increasing geriatric population, and rising cases of various infectious diseases across the world are key factors boosting global market revenue growth. Molecular diagnostic techniques have gained rapid traction over the last few years and are widely used in laboratories, research institutes, and hospitals for various purposes. Increasing investments in research and development activities, growing awareness about faster diagnostic techniques, and increasing adoption of self-testing kits are fueling the revenue growth of the global market. In addition, government funding for developing advanced testing kits and instruments and rapid infrastructural developments in healthcare systems are further supporting global market revenue growth. However, many hospitals and reference laboratories in developing countries find it difficult to afford the costly instruments and kits. This is expected to hamper global market growth in the coming years. In addition, lack of skilled professionals to operate these instruments is expected to further restrain market growth during the forecast period. Get a sample of the report @ https://reportsanddata.com/sample-enquiry-form/945 The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances. Key players in the market include Abbott, Roche Diagnostics, QIAGEN, Danaher, Hologic, Becton, Siemens Healthcare GmbH, Bio-Rad Laboratories, Dickinson and Co., Cepheid Furthermore, the report segments Molecular Diagnostics market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period. Product and Service Outlook (Revenue, USD Billion, 2018 - 2028) • Reagents and Kits • Instruments • Tabletop Instruments • Portable & PoC Instruments • Services and Software Technology Outlook (Revenue, USD Billion, 2018 - 2028) • Polymerase Chain Reaction (PCR) • Isothermal Nucleic Acid Amplification Technology (INAAT) • DNA Sequencing & Next-Generation Sequencing (NGS) • In Situ Hybridization • DNA Microarray • Other Technologies Application Outlook (Revenue, USD Billion, 2018 - 2028) • Infectious Diseases • Hepatitis • HIV • CT/NG • HAIS • HPV • Tuberculosis • Influenza • Other Infectious Diseases • Oncology Testing • Breast Cancer • Colorectal Cancer • Lung Cancer • Prostate Cancer • Other Cancers • Genetic Tests • Others End-Use Outlook (Revenue, USD Billion, 2018 - 2028) • Hospital and Clinics • Diagnostic Laboratories • Others For a better understanding of the global Molecular Diagnostics market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region. Request a discount on the report @ https://reportsanddata.com/discount-enquiry-form/945 In-depth regional analysis includes: • North America (U.S., Canada, Mexico) • Europe (Italy, U.K., Germany, France, Rest of EU) • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA To know more about the report @ https://reportsanddata.com/report-detail/global-molecular-diagnostics-market Key Features of the Global Molecular Diagnostics Market Report: • Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value • Identification and analysis of significant trends and factors driving revenue growth of the market • Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches • Assessment of each market segment along with their growth trends and market revenue contribution • Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks Request a customization of the report @ https://reportsanddata.com/request-customization-form/945 Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements. Browse More Reports : Vaginal Pessary Market Analysis Spinal Trauma Devices Market Share About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
    Molecular Diagnostics Market Share & Analysis, 2018-2028
    The global Molecular Diagnostics market size was USD 8.52 Billion in 2020 and is expected to register a CAGR of 8.2% during the forecast period. The increasing incidence of infectious diseases and the mammoth rise in reported cancer cases is fueling market growth.
    REPORTSANDDATA.COM
    0 Comments 0 Shares

  • According to the current analysis of Reports and Data, The global Immunohistochemistry market was valued at USD 1,736.4 million in 2018 and is expected to reach USD 3,359.8 million by the year 2026, growing at a CAGR of 8.6%.
    Immunohistochemistry (IHC) has crucial applications in the field of tissue distribution of antigens by using monoclonal and polyclonal antibodies. It is used for cancer diagnosis, because it determines the presence of tumor antigens. It is a technique which combines immunological, anatomical, and biochemical processes to identify tissue components by the interaction of target antigens with specific antibodies that are tagged by a label. Immunohistochemistry used by public and private organizations to check localization and distribution of cellular components within the cells.
    Immunohistochemistry is being applied in many other areas. Immunohistochemistry is widely used to predict therapeutic response in two important tumors, i.e. carcinoma of breast and prostate. Both these tumors are under the growth regulation of the hormones estrogen and androgen, respectively. The specific receptors for these growth regulating hormones are located on respective tumor cells. Tumors expressing high level of receptor positivity would respond favorably to removal of the endogenous source of such hormones or hormonal therapy is administered to lower their levels – estrogen therapy in prostate cancer and androgen therapy in breast cancer. Immunohistochemistry techniques are also being applied to confirm infectious agent in tissues by use of specific antibodies against microbial DNA or RNA, e.g. in Cytomegalo virus, Hepatitis B virus, Hepatitis C virus, etc. The application is used routinely in validation of disease targets as it allows visualizing expression of the target in the affected tissue during the disease process. Another important advantage of Immunohistochemistry is that it can also be used to detect organisms in cytological preparations such as fluids, sputum samples, and material obtained from fine needle aspiration procedures. This can be very helpful in certain situations such as detection of pneumocystis from the sputum of an immunocompromised patient who needs rapid and precise confirmation of infection in order to begin immediate and appropriate therapy.
    Specific diagnosis of muscular dystrophy is important because of the genetic counseling implications of inherited disease and accurate prognostication. In recent years, abnormalities in several muscle proteins have been identified in muscular dystrophies. Such abnormalities involve proteins located in the sarcolemma, extracellular matrix, cytosol, nucleus, and other sites within muscle fibers. Skeletal muscle biopsy can play a main role in differentiating vascular dystrophy from non-dystrophic disorders and Immunohistochemistry can assist in establishing a specific diagnosis of the dystrophies for which specific protein abnormalities are known. In the last few years, immunohistochemical staining for beta amyloid precursor protein has been validated as a method to detect axonal injury within as little as 2–3 h of head injury. Immunohistochemical detection of axonal injury can be useful in establishing timing of a traumatic insult in medico-legal settings.
    Rapid growth of healthcare investment in emerging economies and technological development in invitro industry creates the opportunities to manufacturers for Immunohistochemistry kit, equipment and reagents. Growing prevalence of chronic diseases including cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases are the key factors for the growth of the market. Significant rise in R&D spending and shift towards comprehensive healthcare solutions are impelling the market growth.
    Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2198
    The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.
    Key players in the market include
    Abcam plc; Agilent Technologies; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc.
    For a better understanding of the global Immunohistochemistry market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region.
    Furthermore, the report segments Immunohistochemistry market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.
    Type (Revenue, USD Million; 2017–2027)
    • Antibodies
    o Primary Antibodies
    o Secondary Antibodies
    • Equipment
    o Slide Staining Systems
    o Tissue Microarrays
    o Tissue Processing Systems
    o Slide Scanners
    o Others
    • Reagents
    o Histological Stains
    o Blocking Sera and Reagents
    o Chromogenic Substrates
    o Fixation Reagents
    o Stabilizers
    o Organic Solvents
    o Proteolytic Enzymes
    o Diluents
    • Kits

    Application (Revenue, USD Million; 2017–2027)
    • Diagnostics
    o Cancer
    o Infectious Diseases
    o Cardiovascular Diseases
    o Autoimmune Diseases
    o Diabetes Mellitus
    o Nephrological Diseases
    • Drug Testing

    End Use (Revenue, USD Million; 2017–2027)
    • Hospitals and Diagnostic Laboratories
    • Clinics
    • Research Institutes
    • Others

    Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2198
    In-depth regional analysis includes:
    • North America (U.S., Canada, Mexico)
    • Europe (Italy, U.K., Germany, France, Rest of EU)
    • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
    To know more about the report @ https://www.reportsanddata.com/report-detail/immunohistochemistry-market
    Benefits of the Global Immunohistochemistry Report:
    • Comprehensive analysis of the opportunities and risks of the Immunohistochemistry market
    • Detailed study of the latest product and technological developments and innovations of the Immunohistochemistry market
    • Business strategies and plans are analysed for understanding the Immunohistochemistry market scenario
    • Revenue forecast of Immunohistochemistry market for the forecast period 2020-2027
    • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities
    • Latest and emerging market trends analysis and their impact on product and application demand
    • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others
    • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility
    Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2198
    Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.
    Browse More Reports :
    ENT Medical Devices Market Report
    Cryptococcosis Market Research

    About Reports and Data
    Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
    Contact Us:
    John W
    Head of Business Development
    Reports and Data | Web: www.reportsanddata.com
    Direct Line: +1-212-710-1370
    E-mail: sales@reportsanddata.com
    According to the current analysis of Reports and Data, The global Immunohistochemistry market was valued at USD 1,736.4 million in 2018 and is expected to reach USD 3,359.8 million by the year 2026, growing at a CAGR of 8.6%. Immunohistochemistry (IHC) has crucial applications in the field of tissue distribution of antigens by using monoclonal and polyclonal antibodies. It is used for cancer diagnosis, because it determines the presence of tumor antigens. It is a technique which combines immunological, anatomical, and biochemical processes to identify tissue components by the interaction of target antigens with specific antibodies that are tagged by a label. Immunohistochemistry used by public and private organizations to check localization and distribution of cellular components within the cells. Immunohistochemistry is being applied in many other areas. Immunohistochemistry is widely used to predict therapeutic response in two important tumors, i.e. carcinoma of breast and prostate. Both these tumors are under the growth regulation of the hormones estrogen and androgen, respectively. The specific receptors for these growth regulating hormones are located on respective tumor cells. Tumors expressing high level of receptor positivity would respond favorably to removal of the endogenous source of such hormones or hormonal therapy is administered to lower their levels – estrogen therapy in prostate cancer and androgen therapy in breast cancer. Immunohistochemistry techniques are also being applied to confirm infectious agent in tissues by use of specific antibodies against microbial DNA or RNA, e.g. in Cytomegalo virus, Hepatitis B virus, Hepatitis C virus, etc. The application is used routinely in validation of disease targets as it allows visualizing expression of the target in the affected tissue during the disease process. Another important advantage of Immunohistochemistry is that it can also be used to detect organisms in cytological preparations such as fluids, sputum samples, and material obtained from fine needle aspiration procedures. This can be very helpful in certain situations such as detection of pneumocystis from the sputum of an immunocompromised patient who needs rapid and precise confirmation of infection in order to begin immediate and appropriate therapy. Specific diagnosis of muscular dystrophy is important because of the genetic counseling implications of inherited disease and accurate prognostication. In recent years, abnormalities in several muscle proteins have been identified in muscular dystrophies. Such abnormalities involve proteins located in the sarcolemma, extracellular matrix, cytosol, nucleus, and other sites within muscle fibers. Skeletal muscle biopsy can play a main role in differentiating vascular dystrophy from non-dystrophic disorders and Immunohistochemistry can assist in establishing a specific diagnosis of the dystrophies for which specific protein abnormalities are known. In the last few years, immunohistochemical staining for beta amyloid precursor protein has been validated as a method to detect axonal injury within as little as 2–3 h of head injury. Immunohistochemical detection of axonal injury can be useful in establishing timing of a traumatic insult in medico-legal settings. Rapid growth of healthcare investment in emerging economies and technological development in invitro industry creates the opportunities to manufacturers for Immunohistochemistry kit, equipment and reagents. Growing prevalence of chronic diseases including cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases are the key factors for the growth of the market. Significant rise in R&D spending and shift towards comprehensive healthcare solutions are impelling the market growth. Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2198 The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances. Key players in the market include Abcam plc; Agilent Technologies; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc. For a better understanding of the global Immunohistochemistry market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region. Furthermore, the report segments Immunohistochemistry market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period. Type (Revenue, USD Million; 2017–2027) • Antibodies o Primary Antibodies o Secondary Antibodies • Equipment o Slide Staining Systems o Tissue Microarrays o Tissue Processing Systems o Slide Scanners o Others • Reagents o Histological Stains o Blocking Sera and Reagents o Chromogenic Substrates o Fixation Reagents o Stabilizers o Organic Solvents o Proteolytic Enzymes o Diluents • Kits Application (Revenue, USD Million; 2017–2027) • Diagnostics o Cancer o Infectious Diseases o Cardiovascular Diseases o Autoimmune Diseases o Diabetes Mellitus o Nephrological Diseases • Drug Testing End Use (Revenue, USD Million; 2017–2027) • Hospitals and Diagnostic Laboratories • Clinics • Research Institutes • Others Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2198 In-depth regional analysis includes: • North America (U.S., Canada, Mexico) • Europe (Italy, U.K., Germany, France, Rest of EU) • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA) To know more about the report @ https://www.reportsanddata.com/report-detail/immunohistochemistry-market Benefits of the Global Immunohistochemistry Report: • Comprehensive analysis of the opportunities and risks of the Immunohistochemistry market • Detailed study of the latest product and technological developments and innovations of the Immunohistochemistry market • Business strategies and plans are analysed for understanding the Immunohistochemistry market scenario • Revenue forecast of Immunohistochemistry market for the forecast period 2020-2027 • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities • Latest and emerging market trends analysis and their impact on product and application demand • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2198 Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements. Browse More Reports : ENT Medical Devices Market Report Cryptococcosis Market Research About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
    Immunohistochemistry Market | Size, Share | Global Report
    Immunohistochemistry market size is projected to reach USD 3.64 billion by 2027 registering a CAGR of 8.6%. The expanding demand for targeted immunotherapy & biologic therapy for anticancer drug development and increasing FDA approvals are expected to boost the market growth.
    WWW.REPORTSANDDATA.COM
    0 Comments 0 Shares
  • Global Hereditary Cancer Testing Market Share Report Industry Outlook – Latest Development, Trends and Forecast till 2030

    Global Hereditary Cancer Testing Market report has been published by Absolute Markets Insights which includes information from a wide range of resources like established companies, government organizations, industry brokers, trade and industry associations and other such regulatory and non-regulatory bodies. The data acquired from these organizations validate the Global Hereditary Cancer Testing Market research report, thereby aiding the clients in better decision making. Furthermore, the data provided in this report covers a contemporary understanding of the market dynamics. Global Hereditary Cancer Testing Market Research Report also covers in-depth study on the current status of the Global Hereditary Cancer Testing Market industry. It offers key analysis on the market status of the Global Hereditary Cancer Testing Market players with best meaning, SWOT analysis, definition, expert opinions and the recent developments across the globe. The Report also analyze the market size, Price, Gross Margin and Share, Future industry Revenue, cost structure and industrial growth rate.

    Important Features of the report:
    • Detailed analysis of the Global Hereditary Cancer Testing Market
    • Fluctuating market dynamics of the industry
    • Detailed market segmentation
    • Historical, current and projected market size in terms of volume and value
    • Recent industry trends and developments
    • Competitive landscape of the Global Hereditary Cancer Testing Market
    • Strategies of key players and product offerings
    • A neutral perspective towards Global Hereditary Cancer Testing Market performance

    Access Full Research Report of Global Hereditary Cancer Testing Market @ https://www.industryglobalnews24.com/global-hereditary-cancer-testing-market-was-valued-at-us-605137-mn-in-2020-due-to-

    In its newly released report, AMI anticipates that the market will grow at 6.2% owing to technological advancements and increased investments towards enhancement of medical infrastructure. AMI reports that the market stood at a valuation of US$ 6051.37 Mn in 2020.

    A hereditary cancer is defined as any form of cancer that is caused by an inherited gene mutation. An inherited gene is a gene that is passed from parent to child within a family. The factors that suggest a possible increased risk for hereditary cancer include family history, cancer at an early age, and multiple cancers. People who have three or more relatives on the same side of the family suffering from same or related forms of cancer are prone to a cancer that might be hereditary in nature. Some rare types of cancer such as adrenocortical cancer, ovarian cancer, and sarcoma are linked to inherited genetic mutations, and hence, can also be hereditary in nature.

    Some key players in the global hereditary cancer testing market are Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE N.V., Color Health Inc., Fulgent Genetics, Illumina Inc., Invitae Corporation, LifeLabs Genetics, Myogenes Limited, Myriad Genetics Inc., NIPD Genetics, Otogenetics, and others.

    Segmentation of Global Hereditary Cancer Testing Market:
    By Cancer Type
    o Breast Cancer
    o Ovarian Cancer
    o Colon cancer
    o Stomach Cancer
    o Head & Neck Cancer
    o Prostate Cancer
    o Pancreatic Cancer
    o Melanoma
    o Others

    By Test Type
    o Single Gene Testing
    o Multi-Gene Panel Testing

    By End Users
    o Hospitals
    o Clinics
    o Diagnostic
    o Others
    By Region
     North America
    o U.S.
    o Canada
    o Mexico
    o Rest of North America
     Europe
    o France
    o The UK
    o Spain
    o Germany
    o Italy
    o Nordic Countries
     Denmark
     Finland
     Iceland
     Sweden
     Norway
    o Benelux Union
     Belgium
     The Netherlands
     Luxembourg
    o Rest of Europe
     Asia Pacific
    o China
    o Japan
    o India
    o New Zealand
    o Australia
    o South Korea
    o Southeast Asia
     Indonesia
     Thailand
     Malaysia
     Singapore
     Rest of Southeast Asia
    o Rest of Asia Pacific
     Middle East & Africa
    o Saudi Arabia
    o UAE
    o Egypt
    o Kuwait
    o South Africa
    o Rest of Middle East & Africa
     Latin America
    o Brazil
    o Argentina
    o Rest of Latin America
    More Reports@
    https://www.industryglobalnews24.com/find-out-what-are-the-important-factors-boosting-the-demand-of-global-microbial-cell-banking-market-


    https://industryglobalnews24.com/global-brain-monitoring-market-to-grow-at-promising-69-cagr-during-20212029-a-


    Contact us:
    Contact Name: Shreyas Tanna
    Phone: +91-740-024-2424
    Company: Absolute Markets Insights
    Email Id: sales@absolutemarketsinsights.com
    website: https://www.absolutemarketsinsights.com/
    Global Hereditary Cancer Testing Market Share Report Industry Outlook – Latest Development, Trends and Forecast till 2030 Global Hereditary Cancer Testing Market report has been published by Absolute Markets Insights which includes information from a wide range of resources like established companies, government organizations, industry brokers, trade and industry associations and other such regulatory and non-regulatory bodies. The data acquired from these organizations validate the Global Hereditary Cancer Testing Market research report, thereby aiding the clients in better decision making. Furthermore, the data provided in this report covers a contemporary understanding of the market dynamics. Global Hereditary Cancer Testing Market Research Report also covers in-depth study on the current status of the Global Hereditary Cancer Testing Market industry. It offers key analysis on the market status of the Global Hereditary Cancer Testing Market players with best meaning, SWOT analysis, definition, expert opinions and the recent developments across the globe. The Report also analyze the market size, Price, Gross Margin and Share, Future industry Revenue, cost structure and industrial growth rate. Important Features of the report: • Detailed analysis of the Global Hereditary Cancer Testing Market • Fluctuating market dynamics of the industry • Detailed market segmentation • Historical, current and projected market size in terms of volume and value • Recent industry trends and developments • Competitive landscape of the Global Hereditary Cancer Testing Market • Strategies of key players and product offerings • A neutral perspective towards Global Hereditary Cancer Testing Market performance Access Full Research Report of Global Hereditary Cancer Testing Market @ https://www.industryglobalnews24.com/global-hereditary-cancer-testing-market-was-valued-at-us-605137-mn-in-2020-due-to- In its newly released report, AMI anticipates that the market will grow at 6.2% owing to technological advancements and increased investments towards enhancement of medical infrastructure. AMI reports that the market stood at a valuation of US$ 6051.37 Mn in 2020. A hereditary cancer is defined as any form of cancer that is caused by an inherited gene mutation. An inherited gene is a gene that is passed from parent to child within a family. The factors that suggest a possible increased risk for hereditary cancer include family history, cancer at an early age, and multiple cancers. People who have three or more relatives on the same side of the family suffering from same or related forms of cancer are prone to a cancer that might be hereditary in nature. Some rare types of cancer such as adrenocortical cancer, ovarian cancer, and sarcoma are linked to inherited genetic mutations, and hence, can also be hereditary in nature. Some key players in the global hereditary cancer testing market are Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE N.V., Color Health Inc., Fulgent Genetics, Illumina Inc., Invitae Corporation, LifeLabs Genetics, Myogenes Limited, Myriad Genetics Inc., NIPD Genetics, Otogenetics, and others. Segmentation of Global Hereditary Cancer Testing Market: By Cancer Type o Breast Cancer o Ovarian Cancer o Colon cancer o Stomach Cancer o Head & Neck Cancer o Prostate Cancer o Pancreatic Cancer o Melanoma o Others By Test Type o Single Gene Testing o Multi-Gene Panel Testing By End Users o Hospitals o Clinics o Diagnostic o Others By Region  North America o U.S. o Canada o Mexico o Rest of North America  Europe o France o The UK o Spain o Germany o Italy o Nordic Countries  Denmark  Finland  Iceland  Sweden  Norway o Benelux Union  Belgium  The Netherlands  Luxembourg o Rest of Europe  Asia Pacific o China o Japan o India o New Zealand o Australia o South Korea o Southeast Asia  Indonesia  Thailand  Malaysia  Singapore  Rest of Southeast Asia o Rest of Asia Pacific  Middle East & Africa o Saudi Arabia o UAE o Egypt o Kuwait o South Africa o Rest of Middle East & Africa  Latin America o Brazil o Argentina o Rest of Latin America More Reports@ https://www.industryglobalnews24.com/find-out-what-are-the-important-factors-boosting-the-demand-of-global-microbial-cell-banking-market- https://industryglobalnews24.com/global-brain-monitoring-market-to-grow-at-promising-69-cagr-during-20212029-a- Contact us: Contact Name: Shreyas Tanna Phone: +91-740-024-2424 Company: Absolute Markets Insights Email Id: sales@absolutemarketsinsights.com website: https://www.absolutemarketsinsights.com/
    Global Hereditary Cancer Testing Market was Valued at US$ 6051.37 Mn in 2020 due to Increasing Prevalence of Genetic Disorders
    Absolute Markets Insights (AMI) reports a robust growth forecast for the global hereditary cancer testing market during the forecast period (2021 – 2029). In its newly released report, AMI anticipates that the market
    WWW.INDUSTRYGLOBALNEWS24.COM
    0 Comments 0 Shares
  • Prostate Cancer Specialist in Delhi

    #prostatecancer #prostatecancerawareness #prostatecancerspecialist #specialist #healthcare #cancer #prostatehealth
    Prostate Cancer Specialist in Delhi #prostatecancer #prostatecancerawareness #prostatecancerspecialist #specialist #healthcare #cancer #prostatehealth
    Prostate cancer- Symptoms and Prevention in Hindi | Dr. Priya Tiwari
    Prostate cancer Symptoms and Prevention in hindi by Dr Priya Tiwari
    WWW.DRPRIYATIWARI.COM
    0 Comments 1 Shares
  • Prostate Cancer Doctor in Delhi

    #prostatecancer #prostatecancerawareness #prostatecancerdoctor #delhi #Gurgaon #doctor #healthcare #cancer #prostatehealth
    Prostate Cancer Doctor in Delhi #prostatecancer #prostatecancerawareness #prostatecancerdoctor #delhi #Gurgaon #doctor #healthcare #cancer #prostatehealth
    Prostate Cancer | Dr. Priya Tiwari | Medical Oncologist
    Prostate cancer incidence is rising in India. September is prostate cancer awareness month.
    WWW.DRPRIYATIWARI.COM
    0 Comments 1 Shares
  • Prostate cancer treatment in delhi
    Prostate cancer treatment in delhi
    Prostate Cancer in Hindi | Dr. Priya Tiwari | Medical Oncologist
    For more information related to Prostate Cancer and other cancers, you can contact me on the below numbers for an appointment. 8130128241 / 8586930175
    WWW.DRPRIYATIWARI.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored